Miniatura

Fitxers

674831.pdf (645.39 KB)

Tipus de document

Article

Versió

Versió publicada

Data de publicació

2014-09-11

Tots els drets reservats

Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/178508

Angiotensin-neprilysin inhibition versus enalapril in heart failure

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

https://doi.org/10.1056/NEJMoa1409077

Resum

Background: we compared the angiotensin receptor-neprilysin inhibitor LCZ696 with enalapril in patients who had heart failure with a reduced ejection fraction. In previous studies, enalapril improved survival in such patients. Methods: in this double-blind trial, we randomly assigned 8442 patients with class II, III, or IV heart failure and an ejection fraction of 40% or less to receive either LCZ696 (at a dose of 200 mg twice daily) or enalapril (at a dose of 10 mg twice daily), in addition to recommended therapy. The primary outcome was a composite of death from cardiovascular causes or hospitalization for heart failure, but the trial was designed to detect a difference in the rates of death from cardiovascular causes. Results: the trial was stopped early, according to prespecified rules, after a median follow-up of 27 months, because the boundary for an overwhelming benefit with LCZ696 had been crossed. At the time of study closure, the primary outcome had occurred in 914 patients (21.8%) in the LCZ696 group and 1117 patients (26.5%) in the enalapril group (hazard ratio in the LCZ696 group, 0.80; 95% confidence interval [CI], 0.73 to 0.87; P<0.001). A total of 711 patients (17.0%) receiving LCZ696 and 835 patients (19.8%) receiving enalapril died (hazard ratio for death from any cause, 0.84; 95% CI, 0.76 to 0.93; P<0.001); of these patients, 558 (13.3%) and 693 (16.5%), respectively, died from cardiovascular causes (hazard ratio, 0.80; 95% CI, 0.71 to 0.89; P<0.001). As compared with enalapril, LCZ696 also reduced the risk of hospitalization for heart failure by 21% (P<0.001) and decreased the symptoms and physical limitations of heart failure (P=0.001). The LCZ696 group had higher proportions of patients with hypotension and nonserious angioedema but lower proportions with renal impairment, hyperkalemia, and cough than the enalapril group. Conclusions: LCZ696 was superior to enalapril in reducing the risks of death and of hospitalization for heart failure. (Funded by Novartis; PARADIGM-HF ClinicalTrials.gov number, NCT01035255).

Matèries

Angiotensines, Insuficiència cardíaca, Ús terapèutic

Matèries (anglès)

Angiotensins, Heart failure, Therapeutic use

Citació

Col·leccions

Articles publicats en revistes (Ciències Clíniques)

Citació

MCMURRAY, John j.v., PACKER, Milton, DESAI, Akshay s., GONG, Jianjian, LEFKOWITZ, Martin p., RIZKALA, Adel r., ROULEAU, Jean l., SHI, Victor c., SOLOMON, Scott d., SWEDBERG, Karl, ZILE, Michael r., COMÍN COLET, Josep, PARADIGM-HF Investigators and Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. _New England Journal of Medicine_. 2014. Vol. 371, núm. 11, pàgs. 993-1004. [consulta: 20 de gener de 2026]. ISSN: 0028-4793. [Disponible a: https://hdl.handle.net/2445/178508]

Exportar metadades

JSON - METS

Compartir registre